Rating Scales for Medication Adherence in Parkinson's Disease: A Systematic Review for Critique and Recommendations.
Parkinson's disease
medication adherence
psychometrics
rating scale
review
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
25
05
2022
revised:
27
08
2022
accepted:
06
09
2022
entrez:
24
2
2023
pubmed:
25
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Behaviors interfering with medication adherence (MA) are common and often complex in Parkinson's disease (PD), negatively affecting quality of life and undermining the value of clinical trials. The Clinical Outcome Assessments (COA) Scientific Evaluation Committee of the International Parkinson and Movement Disorder Society (MDS) commissioned the assessment of MA rating scales to recommend the use in PD. Critically review the measurement properties of rating scales used to assess MA in PD and to issue recommendations. We conducted systematic review across seven databases to identify structured scales to assess MA in PD. Eligible studies were critically appraised for methodological quality using the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) Risk of Bias checklist. Standards for good measurement properties of the selected scales were summarized narratively using the COSMIN, the MDS-COA Committee methodology, the World Health Organization concepts, and the Ascertaining Barriers to Compliance taxonomy. The certainty of the evidence was determined using the modified Grades of Recommendation, Assessment, Development and Evaluation approach with final assessments (highest to lowest) of "Recommended," "Suggested" and "Listed". Of the nine reviewed scales, none met the designation "Recommended". The Morisky Medication Adherence Scale (MMAS-8); Beliefs Related to Medications Adherence questionnaire, Beliefs about Medication Questionnaire, Medication Adherence Rating Scale, and Satisfaction with Information on Medicines Scale were rated "Suggested". We suggest further work focusing on resolving the problems of the suggested scales or developing a new scale meeting all required criteria.
Sections du résumé
Background
UNASSIGNED
Behaviors interfering with medication adherence (MA) are common and often complex in Parkinson's disease (PD), negatively affecting quality of life and undermining the value of clinical trials. The Clinical Outcome Assessments (COA) Scientific Evaluation Committee of the International Parkinson and Movement Disorder Society (MDS) commissioned the assessment of MA rating scales to recommend the use in PD.
Objective
UNASSIGNED
Critically review the measurement properties of rating scales used to assess MA in PD and to issue recommendations.
Methods
UNASSIGNED
We conducted systematic review across seven databases to identify structured scales to assess MA in PD. Eligible studies were critically appraised for methodological quality using the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) Risk of Bias checklist. Standards for good measurement properties of the selected scales were summarized narratively using the COSMIN, the MDS-COA Committee methodology, the World Health Organization concepts, and the Ascertaining Barriers to Compliance taxonomy. The certainty of the evidence was determined using the modified Grades of Recommendation, Assessment, Development and Evaluation approach with final assessments (highest to lowest) of "Recommended," "Suggested" and "Listed".
Results
UNASSIGNED
Of the nine reviewed scales, none met the designation "Recommended". The Morisky Medication Adherence Scale (MMAS-8); Beliefs Related to Medications Adherence questionnaire, Beliefs about Medication Questionnaire, Medication Adherence Rating Scale, and Satisfaction with Information on Medicines Scale were rated "Suggested".
Conclusions
UNASSIGNED
We suggest further work focusing on resolving the problems of the suggested scales or developing a new scale meeting all required criteria.
Identifiants
pubmed: 36825050
doi: 10.1002/mdc3.13586
pii: MDC313586
pmc: PMC9941935
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
175-189Informations de copyright
© 2022 International Parkinson and Movement Disorder Society.
Références
Mov Disord. 2018 Feb;33(2):208-218
pubmed: 29168899
Cien Saude Colet. 2013 Mar;18(3):855-62
pubmed: 23546212
Saudi Pharm J. 2021 May;29(5):427-433
pubmed: 34135668
Neurol Ther. 2016 Jun;5(1):85-99
pubmed: 27271736
J Med Internet Res. 2020 Oct 9;22(10):e19179
pubmed: 33034566
Parkinsons Dis. 2020 Jul 04;2020:4315489
pubmed: 32714503
Eur J Neurol. 2011 Jul;18(7):980-7
pubmed: 21199185
Syst Rev. 2021 Mar 29;10(1):89
pubmed: 33781348
NPJ Parkinsons Dis. 2017 Jan 9;3:2
pubmed: 28649602
Front Med (Lausanne). 2020 Mar 25;7:103
pubmed: 32269998
Medicine (Baltimore). 2018 Jun;97(23):e10962
pubmed: 29879046
Front Neurol. 2020 Oct 19;11:551696
pubmed: 33192983
Qual Life Res. 2018 May;27(5):1171-1179
pubmed: 29260445
PLoS One. 2015 Apr 24;10(4):e0124275
pubmed: 25909363
Front Neurol. 2019 Jul 31;10:799
pubmed: 31417484
Mov Disord Clin Pract. 2020 Jul 08;7(6):607-615
pubmed: 32775505
Br J Clin Pharmacol. 2012 May;73(5):691-705
pubmed: 22486599
Psychol Med. 1983 Feb;13(1):177-83
pubmed: 6133297
Int J Clin Pract. 2014 Aug;68(8):963-71
pubmed: 24750544
BMC Med Inform Decis Mak. 2020 Aug 11;20(1):183
pubmed: 32782027
J Parkinsons Dis. 2016 Apr 2;6(2):383-92
pubmed: 27061070
JAMA. 2020 Feb 11;323(6):548-560
pubmed: 32044947
Patient Educ Couns. 1999 Jun;37(2):113-24
pubmed: 14528539
JBI Evid Synth. 2021 Aug 25;20(1):260-269
pubmed: 34446669
Neurol Sci. 2013 Nov;34(11):2015-22
pubmed: 23728715
Brain Nerve. 2016 Sep;68(9):1087-1098
pubmed: 27667493
Clin Neuropharmacol. 2018 Jan/Feb;41(1):14-19
pubmed: 29300205
Mov Disord Clin Pract. 2015 Oct 28;3(1):68-72
pubmed: 30363523
J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):249-51
pubmed: 16421131
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
NPJ Parkinsons Dis. 2016 Dec 01;2:16023
pubmed: 28725704
Geriatr Gerontol Int. 2013 Oct;13(4):978-85
pubmed: 23452137
Parkinsonism Relat Disord. 2010 Sep;16(8):513-6
pubmed: 20605106
Patient Prefer Adherence. 2019 Jan 18;13:151-155
pubmed: 30697036
J Clin Hypertens (Greenwich). 2008 May;10(5):348-54
pubmed: 18453793
Schizophr Res. 2000 May 5;42(3):241-7
pubmed: 10785582
Prev Med. 1975 Dec;4(4):417-25
pubmed: 813195
Qual Health Care. 2001 Sep;10(3):135-40
pubmed: 11533420
J Aging Health. 2004 Nov;16(5):591-614
pubmed: 15448274
Med Care. 1986 Jan;24(1):67-74
pubmed: 3945130
J Int Neuropsychol Soc. 2012 Nov;18(6):986-95
pubmed: 22846463
Qual Life Res. 2018 May;27(5):1147-1157
pubmed: 29435801
JAMA Neurol. 2021 Feb 1;78(2):165-176
pubmed: 33136137
Mov Disord. 2007 Apr 30;22(6):822-7
pubmed: 17357141